

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C

Peter Schneider

Page 1/6

Monday, January 25, 2021

## MAIN ARENA 1

- 10:10 – 11:20**      **Late breaking trial session: pioneering approaches and new data for BTK interventions**  
*MODERATOR:*  
Marianne Brodmann  
Michael Lichtenberg  
*PANEL:*  
Francesco Liistro  
Wei Guo
- 10:10 – 10:15      IN.PACT BTK randomized study: 9 month primary outcomes  
Francesco Liistro
- 10:15 – 10:20      Chinese experience of DCB in BTK: 12 month results of the AcoArt II study  
Wei Guo
- 10:20 – 10:25      Latest data of DCB in BTK: 12 month results of the AcoArt BTK Italy study  
Francesco Liistro
- 10:25 – 10:30      Luminor in BTK: MERLION trial 12 month outcomes presented for the first time  
Tjun Yip Tang
- 10:30 – 10:35      Temozolimus adventitial delivery to improve ANGIographic Outcomes below the knee (TANGO)  
Ehrin Armstrong
- 10:35 – 10:40      PRESTIGE-study: 12 month results with the SELUTION sirolimus coated balloon in TASC C and D tibial occlusive disease  
Tze Tec Chong
- 10:40 – 10:45      A pilot study examining the performance and safety of the temporary spur stent system in infrapopliteal arteries: first-time use with a Limus-coated balloon (DEEPER LIMUS)  
Marianne Brodmann
- 10:45 – 10:50      DEEPER OUS trial: a multicenter, single arm trial of the novel temporary spur stent system used in conjunction with a commercially available, paclitaxel-coated balloon  
Michael Lichtenberg
- 10:50 – 10:55      12 month data from the LimFlow PROMISE I US early feasibility study  
**Peter Schneider**

**We are asking all faculty members to strictly respect the given time limits.**

# PROGRAMME

---

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C



Peter Schneider

Page 2/6

**Monday, January 25, 2021**

10:55 – 11:20      Live case transmission from Leipzig  
Universitätsklinikum Leipzig, Abt. Angiologie - Live case center

**We are asking all faculty members to strictly respect the given time limits.**

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C

Peter Schneider

Page 3/6

Wednesday, January 27, 2021

## MAIN ARENA 1

- 19:00 – 20:20**    **VIVA/LINC – Joint session on the current status and future of drug-eluting therapies**  
*MODERATOR:*  
Dierk Scheinert  
**Peter Schneider**  
*PANEL:*  
Andrew Holden  
Marianne Brodmann  
Robert Lookstein
- 19:00 – 19:03    Introduction by the moderators  
Dierk Scheinert  
**Peter Schneider**
- 19:03 – 19:08    Insights on paclitaxel safety from the femoral-popliteal RCTs  
**Peter Schneider**
- 19:08 – 19:13    Insights on paclitaxel safety from femoral-popliteal real-world data  
Eric Secemsky
- 19:13 – 19:18    How does the Voyager data help us understand the risks of paclitaxel?  
Marc Bonaca
- 19:18 – 19:23    Paclitaxel safety in patients with CLTI  
Marianne Brodmann
- 19:23 – 19:28    Newly FDA-approved paclitaxel devices for lower extremity and dialysis and the regulatory implications  
Robert Lookstein
- 19:28 – 19:33    New data on paclitaxel in the next couple of years; what should we expect?  
Eva Freisinger
- 19:33 – 19:45    Panel discussion
- 19:45 – 19:50    Paclitaxel vs. limus agents. Mechanism of action, what are the challenges to move beyond paclitaxel?  
Sahil Parikh

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

LINC

The logo for LINC (Leipzig Interventional Course) features the letters 'LINC' in a bold, sans-serif font. A large, dark blue, brush-stroke-like graphic element curves behind the letters, starting from the bottom left and sweeping upwards and to the right, passing behind the 'I' and 'N'.

Peter Schneider

Page 4/6

## Wednesday, January 27, 2021

- |               |   |
|---------------|---|
| 19:50 – 19:55 | Previous experience with limus compounds in the non-coronary arteries; lessons learned<br>Thomas Zeller   |
| 19:55 – 20:00 | New limus delivering devices for above and below knee occlusive disease; when to expect results?<br>Andrew Holden   |
| 20:00 – 20:10 | Blue horizon keynote speech: Potential for drug delivery in the treatment of lower extremity occlusive disease: what will the practice look like in 5 years?<br>Dierk Scheinert |
| 20:10 – 20:20 | Panel discussion  |

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C

Peter Schneider

Page 5/6

Friday, January 29, 2021

## MAIN ARENA 1

- 10:45 – 12:15**      **Pioneering techniques and new data for CLI treatment**  
*MODERATOR:*  
Roberto Ferraresi  
Marianne Brodmann  
*PANEL:*  
Steven Kum  
Jean-Paul de Vries  
Giacomo Clerici
- 10:45 – 10:50      CO<sub>2</sub> angiography guided interventions in critical limb ischemia: how to do it?  
Luis Palena
- 10:50 – 11:20      Live case transmission from Abano Terme  
Policlinico Abano Terme - Live case center
- 11:20 – 11:25      Medial artery calcification (MAC) and it's relevance for wound healing and limb salvage  
Roberto Ferraresi
- 11:25 – 11:30      Imaging techniques to determine tissue perfusion in critical limb ischemia  
Marianne Brodmann
- 11:30 – 11:35      Applicability of hyperspectral imaging to determine tissue perfusion in peripheral arterial disease  
Jean-Paul de Vries
- 11:35 – 11:40      The concept of deep venous arterialization (DVA) – how do DVA results compare with standard revascularization techniques?  
Miguel Montero-Baker
- 11:40 – 11:55      Recorded case: deep venous arterialization  
Andrej Schmidt
- 11:55 – 12:00      Comparison of outcomes from the latest LimFlow data from the PROMISE I (12 month data) and ALPS (24 month data)  
**Peter Schneider**
- 12:00 – 12:05      Post DVA patient management and wound care strategy  
Giacomo Clerici

**We are asking all faculty members to strictly respect the given time limits.**

# PROGRAMME

---

LEIPZIG  
INTERVENTIONAL  
COURSE

LINC



Peter Schneider

Page 6/6

Friday, January 29, 2021

- |               |  |
|---------------|--|
| 12:05 – 12:10 | DVA tips/tricks and lessons learned<br>Daniel van den Heuvel |
| 12:10 – 12:15 | Discussion and conclusion                                    |

We are asking all faculty members to strictly respect the given time limits.